Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, The Netherlands.
Contrast Media Mol Imaging. 2011 Jan-Feb;6(1):19-27. doi: 10.1002/cmmi.398. Epub 2010 Jul 21.
In vivo molecular imaging with targeted MRI contrast agents will require sensitive methods to quantify local concentrations of contrast agent, enabling not only imaging-based recognition of pathological biomarkers but also detection of changes in expression levels as a consequence of disease development, therapeutic interventions or recurrence of disease. In recent years, targeted paramagnetic perfluorocarbon emulsions have been frequently applied in this context, permitting high-resolution (1)H MRI combined with quantitative (19)F MR imaging or spectroscopy, under the assumption that the fluorine signal is not altered by the local tissue and cellular environment. In this in vitro study we have investigated the (19)F MR-based quantification potential of a paramagnetic perfluorocarbon emulsion conjugated with RGD-peptide to target the cell-internalizing α(ν)β(3)-integrin expressed on endothelial cells, using a combination of (1)H MRI, (19)F MRI and (19)F MRS. The cells took up the targeted emulsion to a greater extent than nontargeted emulsion. The targeted emulsion was internalized into large 1-7 µm diameter vesicles in the perinuclear region, whereas nontargeted emulsion ended up in 1-4 µm diameter vesicles, which were more evenly distributed in the cytoplasm. Association of the targeted emulsion with the cells resulted in different proton longitudinal relaxivity values, r(1), for targeted and control nanoparticles, prohibiting unambiguous quantification of local contrast agent concentration. Upon cellular association, the fluorine R(1) was constant with concentration, while the fluorine R(2) increased nonlinearly with concentration. Even though the fluorine relaxation rate was not constant, the (19)F MRI and (19)F MRS signals for both targeted nanoparticles and controls were linear and quantifiable as function of nanoparticle concentration.
体内靶向磁共振对比剂的分子成像需要敏感的方法来定量局部对比剂浓度,不仅能够基于成像识别病理生物标志物,还能够检测到疾病发展、治疗干预或疾病复发导致的表达水平变化。近年来,靶向超顺磁氟碳乳液在这方面得到了广泛应用,允许进行高分辨率(1)H MRI 与定量(19)F MR 成像或光谱学相结合,假设氟信号不受局部组织和细胞环境的影响。在这项体外研究中,我们使用(1)H MRI、(19)F MRI 和(19)F MRS 相结合,研究了靶向与 RGD 肽偶联的超顺磁氟碳乳液的(19)F MR 定量潜力,该乳液靶向内皮细胞内化的α(ν)β(3)-整联蛋白。靶向乳液被细胞摄取的程度高于非靶向乳液。靶向乳液被内化到核周区的 1-7 µm 直径大泡中,而非靶向乳液则聚集在 1-4 µm 直径的小泡中,这些小泡在细胞质中分布更均匀。靶向乳液与细胞结合导致靶向和对照纳米颗粒的质子纵向弛豫率 r(1)值不同,从而禁止对局部对比剂浓度进行明确的定量。在细胞结合后,氟的 R(1)值与浓度保持恒定,而氟的 R(2)值随浓度呈非线性增加。尽管氟的弛豫率不是恒定的,但靶向纳米颗粒和对照物的(19)F MRI 和(19)F MRS 信号都是线性的,可以作为纳米颗粒浓度的函数进行定量。